This proposal details a 5-year training program and is designed to prepare the principal investigator for a career in academic medicine. The principal investigator has fulfilled clinical requirements for internal medicine at the Johns Hopkins Hospital and cardiology fellowship at Brigham and Women's Hospital. The program encourages the acquisition of sound principles and expertise for studying the transcriptional co-activator, PPAR gamma co-activator 1 alpha (PGC1-alpha), as it pertains to metabolism. Bruce M. Spiegelman, Ph.D. is a pioneer in the field of energy metabolism and will mentor the principal investigator by providing career and scientific guidance. The research endeavors to elucidate the role of the PGC1-alpha holo-complex in diabetes and energy metabolism. Prior genetic studies in the laboratory identified several transcription factors regulated by PGC1- alpha and highlighted the pivotal role of PGC1-alpha in energy homeostasis. The proteome is the final determinant of cellular phenotype, and we hypothesize that characterization of the PGC1-alpha holo-complex will identify novel factors that regulate diabetes and energy metabolism.
Specific aims of the project are: 1) Establish a versatile technique to isolate PGC1-alpha holo-complexes. 2) Elucidate the proteins comprising the PGC1-alpha holo-complex from normal and diabetic tissues. 3) Characterize the molecular and biological significance of the PGC1-alpha complex. This study constitutes the first functional and proteomic analysis of the PGC1-alpha holo-complex, and may define new regulatory roles for PGC1-alpha in diabetes. The department of Cancer Biology at the Dana-Farber Cancer Institute provides a stimulating and scientifically sound base from which the principal investigator can build a career in academic medicine. Ultimately, the environment and the program will foster the development of the principal investigator into an independent physician-scientist.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
1K08DK071017-01
Application #
6912253
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Hyde, James F
Project Start
2005-05-01
Project End
2010-04-30
Budget Start
2005-05-01
Budget End
2006-04-30
Support Year
1
Fiscal Year
2005
Total Cost
$130,962
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Liu, Lijun; Sanosaka, Masato; Lei, Shi et al. (2011) LRP130 protein remodels mitochondria and stimulates fatty acid oxidation. J Biol Chem 286:41253-64
Estall, Jennifer L; Kahn, Mario; Cooper, Marcus P et al. (2009) Sensitivity of lipid metabolism and insulin signaling to genetic alterations in hepatic peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression. Diabetes 58:1499-508
Cooper, Marcus P; Uldry, Marc; Kajimura, Shingo et al. (2008) Modulation of PGC-1 coactivator pathways in brown fat differentiation through LRP130. J Biol Chem 283:31960-7
Cooper, Marcus P; Qu, Lishu; Rohas, Lindsay M et al. (2006) Defects in energy homeostasis in Leigh syndrome French Canadian variant through PGC-1alpha/LRP130 complex. Genes Dev 20:2996-3009